Cyclo Therapeutics Company Insiders
| CYTHW Stock | USD 0.09 0.03 23.33% |
Cyclo Therapeutics employs about 8 people. The company is managed by 10 executives with a total tenure of roughly 19 years, averaging almost 1.0 years of service per executive, having 0.8 employees per reported executive. Recap of Cyclo Therapeutics' management performance can provide insight into the venture performance.
Cyclo |
Cyclo Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (2.8427) % which means that it has lost $2.8427 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (226.6391) %, meaning that it generated substantial loss on money invested by shareholders. Cyclo Therapeutics' management efficiency ratios could be used to measure how well Cyclo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Cyclo Therapeutics Workforce Comparison
Cyclo Therapeutics is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 20,906. Cyclo Therapeutics adds roughly 8.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Cyclo Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyclo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyclo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cyclo Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cyclo Therapeutics Notable Stakeholders
A Cyclo Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cyclo Therapeutics often face trade-offs trying to please all of them. Cyclo Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cyclo Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joshua Fine | CFO Secretary | Profile | |
| E Strattan | Founder Director | Profile | |
| Michael Lisjak | Global Development | Profile | |
| George Fails | Ex Mang | Profile | |
| Jeffrey Tate | Chief COO | Profile | |
| Scott Fine | CEO Director | Profile | |
| Lori McKenna | Global Advocacy | Profile | |
| Sharon Hrynkow | VP Officer | Profile | |
| Lori Gorski | Global Advocacy | Profile | |
| Karen FFPM | Interim Officer | Profile |
About Cyclo Therapeutics Management Performance
The success or failure of an entity such as Cyclo Therapeutics often depends on how effective the management is. Cyclo Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cyclo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cyclo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cyclo Therapeutics, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida. Cyclo Therapeutics is traded on NASDAQ Exchange in the United States.
Please note, the imprecision that can be found in Cyclo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cyclo Therapeutics. Check Cyclo Therapeutics' Beneish M Score to see the likelihood of Cyclo Therapeutics' management manipulating its earnings.
Cyclo Therapeutics Workforce Analysis
Traditionally, organizations such as Cyclo Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cyclo Therapeutics within its industry.Cyclo Therapeutics Manpower Efficiency
Return on Cyclo Therapeutics Manpower
| Revenue Per Employee | 134.6K | |
| Revenue Per Executive | 107.6K | |
| Net Loss Per Employee | 2.5M | |
| Net Loss Per Executive | 2M | |
| Working Capital Per Employee | 481.3K | |
| Working Capital Per Executive | 385K |
Additional Tools for Cyclo Stock Analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.